- Home
- WIMI vs APLT Comparison
WIMI vs APLT Comparison
Compare WIMI & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIMI
- APLT
- Stock Information
- Founded
- WIMI 2015
- APLT 2016
- Country
- WIMI China
- APLT United States
- Employees
- WIMI N/A
- APLT N/A
- Industry
- WIMI Computer Software: Prepackaged Software
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- WIMI Technology
- APLT Health Care
- Exchange
- WIMI Nasdaq
- APLT Nasdaq
- Market Cap
- WIMI 94.3M
- APLT 80.3M
- IPO Year
- WIMI 2020
- APLT 2019
- Fundamental
- Price
- WIMI $0.74
- APLT $0.50
- Analyst Decision
- WIMI
- APLT Buy
- Analyst Count
- WIMI 0
- APLT 7
- Target Price
- WIMI N/A
- APLT $6.10
- AVG Volume (30 Days)
- WIMI 4.6M
- APLT 2.6M
- Earning Date
- WIMI 01-01-0001
- APLT 05-08-2025
- Dividend Yield
- WIMI N/A
- APLT N/A
- EPS Growth
- WIMI N/A
- APLT N/A
- EPS
- WIMI N/A
- APLT N/A
- Revenue
- WIMI $84,137,968.00
- APLT N/A
- Revenue This Year
- WIMI N/A
- APLT N/A
- Revenue Next Year
- WIMI N/A
- APLT $2,426.33
- P/E Ratio
- WIMI N/A
- APLT N/A
- Revenue Growth
- WIMI 19.25
- APLT N/A
- 52 Week Low
- WIMI $0.63
- APLT $0.43
- 52 Week High
- WIMI $2.92
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- WIMI 41.87
- APLT 38.29
- Support Level
- WIMI $0.68
- APLT $0.49
- Resistance Level
- WIMI $0.75
- APLT $0.61
- Average True Range (ATR)
- WIMI 0.08
- APLT 0.06
- MACD
- WIMI -0.00
- APLT 0.03
- Stochastic Oscillator
- WIMI 14.21
- APLT 37.68
Stock Price Comparison Chart: WIMI vs APLT
About WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings primarily consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.